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Sphingomyelin as a myelin 
biomarker in CSF of acquired 
demyelinating neuropathies
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Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans 
and experimental models. The overall objective of the present study was to demonstrate that 
sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies 
is a myelin biomarker. We found that SM levels mirror both peripheral myelination during development 
and small myelin rearrangements in experimental models. As in acquired demyelinating peripheral 
neuropathies myelin breakdown occurs, SM amount in the CSF of these patients might detect the 
myelin loss. Indeed, quantification of SM in 262 neurological patients showed a significant increase 
in patients with peripheral demyelination (p = 3.81 * 10 − 8) compared to subjects affected by non-
demyelinating disorders. Interestingly, SM alone was able to distinguish demyelinating from axonal 
neuropathies and differs from the principal CSF indexes, confirming the novelty of this potential CSF 
index. In conclusion, SM is a specific and sensitive biomarker to monitor myelin pathology in the CSF of 
peripheral neuropathies. Most importantly, SM assay is simple, fast, inexpensive, and promising to be 
used in clinical practice and drug development.
Myelin disorders negatively influence wellness of patients for most of their life. Existing treatments may delay the 
disease progression and symptoms, but remyelination promoting compounds have been recently identified only 
in experimental studies1. Moreover, experience from completed and ongoing clinical trials and natural history 
studies confirms difficulties in detecting clinical changes for most of these disorders, making urgent the identifi-
cation of sensitive-to-change outcome measures. In this context, biological markers can serve many unique pur-
poses, including confirmation of diagnosis, monitoring disease progression or treatment effects, and prediction 
of clinical outcome. Biomarkers also play an important role in the preclinical assessment of potentially benefi-
cial and harmful effects of new candidate drugs. Screening tests in animals using biomarkers provide important 
demonstration that a compound is likely to have the intended therapeutic activity in patients. The development of 
effective biomarkers, allowing a better prediction of the disease severity, will ensure a more precise understanding 
of the pathomechanisms, avoiding costly and lifelong unnecessary treatments2.
At present, the amount of myelin may be assessed only in the central nervous system (CNS) of human patients 
by sophisticated techniques3, 4. These systems are quite expensive and require extensive time commitment and 
specific expertise which make them unsuitable for daily clinical practice. Moreover, to the best of our knowledge, 
similar techniques are not employed in peripheral nervous system (PNS) diseases to rate the degree of myelina-
tion5–7. Furthermore, to realistically monitor myelin membranes in human patients, the only option is the identi-
fication of an easily detectable biomarker in biological fluids8. The higher lipid-to-protein ratio and unique lipid 
composition of myelin prompted us to focus on the lipid component of the myelin sheath9.
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Here, we test sphingomyelin (SM), a myelin enriched lipid, by a fluorescence-based assay in different experi-
mental settings to provide proof of concept that its levels are sensitive, specific and reliable to monitor peripheral 
myelination and myelin remodeling. Cerebrospinal fluid (CSF) of patients affected by immune-mediated demy-
elinating neuropathies was used to demonstrate that SM identifies myelin breakdown in these patients.
Results
Our major objective was to identify a fast, reliable and feasible myelin biomarker. Therefore, we had to: i) identify 
a marker sensitive and specific to detect even small myelin rearrangements using an assay of widespread applica-
tion; ii) demonstrate the value of this myelin biomarker for human patients.
SM monitors peripheral myelination during development and small myelin rearrangements. 
We optimised, in peripheral myelinated tissues and cultures, a fluorescence-based assay to quantify SM, an essen-
tial structural and functional component of the myelin membranes9. First, we established a standard curve for 
SM to obtain absolute concentration (nmol) from fluorescence signal. This curve showed both a linear regression 
from 0.2 to 1.6 nmol of input SM and high sensitivity at very low concentrations (<0.02 nmol) (Fig. 1A and 
Supplementary Figure S2). At concentrations higher than 1.6 nmol the curve was less linear and fits a hyperbola 
regression equation understimating the SM amount.
To demonstrate SM specific enrichment in the myelin sheath, we compared its levels in a myelinated tissue 
of PNS, namely sciatic nerve, with those of other non-myelinated tissues (liver, spleen and lung) of adult rats. 
As shown in Fig. 1B, sciatic nerves contained five times more SM than non-myelinated tissues. Moreover, we 
quantified SM during postnatal development in sciatic nerves at different time points (i.e. 3-, 30-, 365- day-old 
rats). We found a massive enrichment of SM content during the first 30 days after birth, mimicking the timing of 
internode maturation of the myelin sheath (Fig. 1C). Afterwards, as already known for myelin, SM stabilised up 
to one year10. To further address this point, we also measured cholesterol levels in the same nerves11. Interestingly, 
even cholesterol, that is rate-limiting for the development of the myelin sheath, showed the same trend over time 
(Supplementary Figure S1). In addition, to further strengthen the specificity of SM to monitor the myelin mem-
brane, we quantified its levels in purified myelin extracts from rat sciatic nerves at similar time points (i.e. 3-, 40-, 
300-day-old rats). Again, we found a remarkable increase of SM up to 40 days (Fig. 1D).
Finally, to demonstrate that SM was able to monitor even small myelin rearrangements, we quantified its levels 
in a chemically induced in vitro model of peripheral demyelination and remyelination12. The decrease of SM con-
tent closely paralleled dose-dependent demyelination elicited by forskolin (Fsk) supplementation to myelinating 
dorsal root ganglia (DRG) cultures. Notably, remyelination occurring after Fsk removal, was matched with a 
corresponding increase of SM levels (Fig. 1E–G).
SM is a biomarker of myelin breakdown in human CSF. After obtaining evidence that SM is a myelin 
marker in experimental models, we tested our hypothesis on the CSF of patients affected by immune-mediated 
demyelinating neuropathies. In particular, we speculated that demyelination at tissue level might be detected 
by SM dosage in the CSF of these patients13–15. In fact, proximal nerve roots located in the subarachnoid region 
are in close contact with CSF. Therefore, the altered composition of CSF could mirror the damage within the 
tissue of the nervous system16. First, we optimised a fluorescence-based assay to quantify SM in CSF that we 
routinely collect for clinical practice (Supplementary Figures S2 and S3). Then, we quantified SM in a cohort of 
patients with definite immune-mediated, demyelinating neuropathies in which myelin breakdown occurs also in 
the nerve roots in close contact with CSF. To exclude a role of blood brain barrier (BBB) in the determination of 
CSF SM levels, patients affected by other non-demyelinating neurological disorders and patients showing obvious 
BBB dysfunction but not overt demyelination were used as two distinct control groups. Interestingly, we found 
that SM was significantly higher in the CSF of patients affected by demyelinating neuropathies both compared 
to the control (p = 3.81 * 10 − 8) and BBB dysfunction (p = 1.34 * 10 − 7) groups (Fig. 2A). Most importantly, 
in all patients the contribution of serum-deriving SM was not relevant, excluding a passive diffusion from the 
periphery (Fig. 2B).
To assess the specificity of the fluorescence-based assay, we analysed the same CSF samples by liquid chroma-
tography tandem mass spectrometry (LC-MS/MS), an advanced technique able to quantify any lipid metabolites. 
Interestingly, a detailed targeted-SM analysis confirmed the striking increase of the most represented SM species 
in the CSF of patients with peripheral demyelination (Fig. 2C,D).
To test the discriminatory power of SM to identify demyelination in CSF, we ran a receiver operating charac-
teristic (ROC) curve analysis and defined the optimal cut-off value in the previously defined groups of patients. 
We found that the area under the curve (AUC) for SM was 0.945, indicative of a good discriminatory biomarker. 
The SM cut-off for optimum sensitivity and specificity was 0.00118 nmol/µl (Fig. 2E,F).
Moreover, we correlated SM with available neurophysiology in 12 out of 15 patients affected by peripheral 
demyelinating neuropathies. A significant inverse correlation was found between SM and peroneal motor con-
duction velocity (MCV). Instead, SM did not correlate with amplitude of compound motor action potential 
(cMAP) of the same nerves (Supplementary Figure S4).
Notably, SM alone was able to distinguish demyelinating from axonal neuropathy. In fact, when we compared 
patients with peripheral demyelination both acute (Guillain-Barrè syndrome, GBS) and chronic (chronic inflam-
matory demyelinating polyradiculoneuropathy, CIDP) with those showing axonopathy, we found a significant 
difference between the two groups (Fig. 3).
Next, we generated a graph in which we plotted for each of the 262 analysed samples SM and albumin quotient 
(QAlb) values, resembling Reiber’s diagram17. Patients were not randomly distributed but clustered in at least 
three groups (Fig. 4). Based on discharge report, among patients with SM over the cut-off, 31 out of 39 patients 
showed clinical and neurophysiological evidence of peripheral demyelination. Accordingly, among patients with 
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SM under the cut-off, only 15 out of 223 patients displayed sign of peripheral demyelination, independently from 
the presence or absence of BBB dysfunction (Table 1).
To support the potential novelty of this marker, we also compared SM with QAlb and immunoglobulins G 
quotient (QIgG) in patients showing BBB dysfunction but not demyelination. We focused on this group as the 
peripheral demyelinating patients were positive either for QAlb and SM, thus making awkward separate demyeli-
nation from inflammation. SM did not correlate with QIgG and poorly with QAlb in 57 patients. Conversely, as 
expected, QAlb and QIgG strongly correlated in the same patients (Supplementary Figure S5).
Figure 1. SM levels mirror both peripheral myelination during development and small myelin rearrangements 
(A) SM titration curve of a fluorescence-based assay showed a significant and reliable linearity from 0.2 to 
1.6 nmol. (B) Quantification of SM in several tissues from 270-day-old rats displayed a specific enrichment 
in sciatic nerves. (C,D) SM levels in rat sciatic nerves and purified myelin progressively increased during 
development (sciatic nerve: 3-day-old, n = 5; 30-day-old, n = 8; 365-day-old, n = 3; purified myelin: 3-day-old, 
n = 3; 40-day-old, n = 3; 300-day-old, n = 3). (E). We treated DRG cultures with Forskolin (Fsk) 20 and 40 μM 
to induce demyelination and then let them recover by Fsk removal. We found that SM was able to detect both 
demyelination and remyelination (n = 6). (F,G) Immunofluorescence staining of myelin by MBP in DRG 
cultures and quantification of MBP-positive myelinated fibers supported biochemical data. Scale bars: 100 µm. 
Errors bars in A, B represent the SD; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns = not-significant. 
Goodness of fit (r2) was determined by linear regression analysis. Holm-Sidak multiple comparison test after 
1-way analysis of variance was used for statistical comparison in B-E.
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Discussion
A growing number of studies proved several biomarkers to be associated with the pathogenesis, development, 
and even recovery of demyelinating neuropathies, although critical issues emerge which restrict their widespread 
acceptance in clinical practice16.
In this study, we have explored a lipid myelin biomarker by a simple, inexpensive, reliable, and rapid 
fluorescence-based assay. In fact, a limiting factor for myelin disorders is the lack of de-remyelination biomarkers 
specific and sensitive to monitor myelin remodeling, to test putative pro-remyelinating compounds and thereby 
select specific treatments. Moreover, myelin is mainly composed by lipids and their derangement has been 
Figure 2. SM is increased in patients affected by demyelinating neuropathies. (A,B) We assessed SM in 
clinically well-characterized subgroups of patients affected by: definite demyelinating neuropathies, namely 
GBS and CIDP (Black bar, Demyelinating neuropathies, n = 14), neurological disorders with blood brain barrier 
dysfunction but not overt demyelination (Grey bar, BBB dysfunction, n = 13), and other non-demyelinating 
neurological disorders (White bar, Ctrl, n = 15). We demonstrated that SM was significantly increased in 
patients with demyelinating neuropathies compared to both the control groups. Interestingly, SM exclusively 
increased in the CSF of these patients to exclude a direct exchange with peripheral blood. (C,D) LC-MS/MS 
targeted-sphingomyelin analysis showed that the total SM species contribution is definitely consistent with 
those obtained by the fluorescence-based assay. 16:0, 18:0, 24:0, 24:1 are the most abundant SM species with 
different saturated and unsaturated fatty acid chains. (E) Specificity and sensitivity of SM assay were tested by 
ROC curve analysis (F) A cut-off value for SM was also calculated. ***p < 0.001, ****p < 0.0001, ns = not-
significant. Holm-Sidak multiple comparison test after 1-way analysis of variance was used for statistical 
comparison in (A–D). ROC implementation in Mathworks MATLAB environment was used in E, F.
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demonstrated in most of these diseases9, 18–20. In particular, we focused on SM due to specific enrichment and 
essential structural role in myelin sheath, both in CNS and PNS9, 21.
Our first interest was to demonstrate that SM levels monitor the myelin amount. Our results clearly show 
that SM assay is able to detect and quantify myelin content in normal rodent peripheral nerves and puri-
fied myelin during development, and subtle changes of myelin levels in an in vitro model of peripheral 
demyelination-remyelination. This finding is extremely relevant in different conditions including pre-clinical 
trials in which may be awkward to monitor small myelin rearrangements following pharmacological and 
non-pharmacological therapies. Indeed, to definitely demonstrate that SM dosage is able to monitor remyelina-
tion in vivo, namely in the CSF, additional experiments are needed on animal models in which peripheral de- and 
remyelination can be exactly and reliably monitored.
To realistically translate these results to humans, we had to test this myelin biomarker in biological fluids. In 
neurological patients, peripheral blood and CSF are the main and ideal source of biomarkers8, 22. In fact, nervous 
tissue exchanges metabolites with blood and CSF; demyelinating processes, causing the breakdown of the mye-
lin membranes to individual constituents, is associated with the liberation of them to the blood/CSF compart-
ments13–15. Thus, we hypothesized that demyelination at tissue level might be detected by SM dosage in the CSF. 
Figure 3. SM is able to distinguish axonal from demyelinating neuropathies. SM alone was significantly 
increased in patients affected by demyelinating neuropathies (n = 14) compared to those affected by axonal 
neuropathies (n = 8). ***p < 0.001. Unpaired 2-tailed t-test was used for statistical comparison.
Figure 4. SM is a biomarker of myelin breakdown in the CSF of human patients. A scatter plot of all the 262 
analysed patients based on QAlb and SM cut-off (X and Y axis, respectively) is shown. Notably, most of the 
patients with peripheral demyelination (Black circles) were over the SM threshold. Control subjects, either with 
or without BBB dysfunction (Grey and white circles, respectively) were also reported in the graph. Grey lines 
represent SM (Y axis) and QAlb (X axis) cut-off.
Patient CSF data ↓QAlb ↑QAlb
↓SM 158 (1/158 Demyelinated) 65 (14/65 Demyelinated) 223 (15/223 Demyelinated) 7%
↑SM 6 (4/6 Demyelinated) 33 (27/33 Demyelinated) 39 (31/39 Demyelinated) 79%
262 Total patients
Table 1. Patients distribution according to SM values. ↓SM = CSF Sphingomyelin under the cut-off; ↑SM = CSF 
Sphingomyelin over the cut-off; ↓QAlb = CSF QAlb index under the cut-off; ↑QAlb = CSF QAlb index over the 
cut-off.
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Therefore, to test our hypothesis, we selected patients affected by immune-mediated demyelinating polyradiculo-
neuropathies in which myelin breakdown may involve spinal roots and is therefore in close contact to CSF; more 
importantly, spinal tap is routinely performed for diagnostic purposes in these cases16. We found that SM is signif-
icantly increased in the CSF of these patients compared to all the control groups (Fig. 2A). Our result is even more 
interesting as SM does not change in the serum, excluding the contribution of peripheral SM (Fig. 2B). Moreover, 
SM-targeted analysis by LC-MS/MS confirmed the increased levels of SM species in the CSF of patients with 
peripheral demyelination. Therefore, we can conclude that the performance of our low-cost assay is in line with 
much more expensive techniques, in terms of accuracy and sensitivity in quantification of the total SM content.
As retrospective, cross-sectional studies, like this one, have significant limits, we refined our approach to sus-
tain the conclusions. First, the accuracy of our results was quantified by ROC curve analysis that demonstrated a 
good discriminatory power for SM and allowed to define a SM cut-off.
Then, based on these results, we extended the analysis up to 262 CSF samples collected from neurological 
patients. Notably, 79% of patients with SM over the threshold show signs of peripheral demyelination, while 
only 7% of those with low SM present peripheral myelin deficit (Table 1). Interestingly, patients with higher SM 
represented 15% of the entire population, identifying a novel, substantial and previously undistinguishable group.
Inside the whole population, 31 patients were affected by axonal neuropathy of different etiology, including 
diabetic and chemotherapy-induced neuropathies. Interestingly, 28 of them (90%) showed SM under the thresh-
old. Thus, SM alone distinguishes demyelinating neuropathies from other non-demyelinating neurological dis-
orders, including axonal neuropathies. To the best of our knowledge, these two clinical phenotypes are currently 
identify only by neurophysiology but simple and reliable methods are not available. In our opinion, this is the first 
of possible applications of SM assay in clinical practice.
Concerning patients in which SM levels do not match with the clinical phenotype, we speculate that one 
reason may lie in the restricted sample size used to define SM cut-off. In fact, several of these patients are located 
close to SM threshold and they would be likely correctly recognized by a more realistic cut-off which can be 
only calculated on a wider population of well-characterized demyelinating patients. Finally, at present it is quite 
difficult to compare SM with quantitative markers of myelin damage as there are no gold standards or validate 
biomarkers in this field.
We also wondered whether SM overlapped with QAlb and QIgG, parameters usually associated to BBB dys-
function and inflammation17. Indeed, we demonstrated that SM discerns an original group of patients inde-
pendently from commonly used CSF indexes (Supplementary Figure S5). This is a relevant issue because most 
of demyelinating disorders have a strong inflammatory/immunological component and a specific and reliable 
myelin biomarker, able to separate demyelination from inflammation, is crucial and highly needed.
Another critical issue is that clinical application of many biomarkers may be limited by expensive methods, 
invasive examinations and low sensitivity/specificity16. The SM assay largely satisfies these requirements. In fact, 
it is: i) simple and easily amenable to routine utilization without the need for sophisticated equipment or operator 
skill; ii) fast, allowing the simultaneously evaluation of more than one hundred samples; iii) inexpensive, with a 
total estimated cost of five euro/sample; iv) reliable, being measured with acceptable accuracy, precision, robust-
ness, and reproducibility, as shown in this study.
To definitely assess the clinical relevance of SM, a multicenter, prospective longitudinal study would be advis-
able to capture a larger number of patients affected by immune-mediated demyelinating neuropathies. To further 
strengthen the meaning and value of this myelin biomarker, it will be extremely interesting to translate these evi-
dences to central demyelination, namely multiple sclerosis. This would allow us to candidate SM assay as a novel 
CSF index to be routinely used in neurological clinical practice.
Methods
Animals. Sprague-Dawley rats were used for the experiments. Research protocols presented in this study are 
conducted in accordance with the ARRIVE guidelines, and are included in those reviewed and approved by the 
OPBA (Institutional Animal Welfare Body) and by the Italian Ministry of Health.
Myelin purification. A light-weight membrane fraction enriched for myelin was purified from rat sciatic 
nerves homogenized in 0.27 M sucrose according to Larocca and Norton23.
In vitro peripheral demyelination/remyelination. A demyelination/remyelination experimental setting 
established on myelinating DRG cultures was used. Briefly, Fsk supplementation of myelinating DRG cultures 
causes demyelination that is reversed by Fsk withdrawal12. DRG cultures were used either for immunofluores-
cence staining of the myelin sheath and SM dosage24, 25. In particular, myelin staining was performed using a 
primary monoclonal antibody against the myelin basic protein (MBP) (MAB 382, Merck Millipore) and a sec-
ondary goat anti-mouse ALEXA594-IgG antibody, as previously described24. Images were taken with an Olympus 
PROVIS AX60 microscope, connected to an Olympus DP70 digital camera. To quantify MBP, we calculated the 
percentage of myelinated area expressed as the area of pixels positive for the red staining of MBP compared to the 
total area of the acquired image. To quantify SM, cultures were scraped and recovered from the culture dishes by 
centrifugation. Resulting pellets were hand-held homogenized in 0.25% Triton X-100 and stored at −80 °C until 
lipid extraction and SM dosage.
Subjects. We performed a cross-sectional retrospective study on the CSF of 262 neurological patients col-
lected between 2014 and 2015 from our laboratory of analysis. The Regional Ethics Committee IRCCS AOU San 
Martino – IST (CER Liguria) approved the current study protocol. Informed consent to use CSF and serum was 
obtained from all the patients involved in the study. We examined CSF of patients authorizing access to personal 
health information according to the Helsinki Declaration as revised in 2013. Samples of patients positive for 
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HCV, HIV and bacterial and viral encephalitis and meningitis were excluded from the study. Samples of patients 
affected by suspected or definite multiple sclerosis were not included in the present study, as they will be discussed 
in a dedicated paper. We used three well-characterized sub-groups of patients to define the sensitivity and speci-
ficity of SM assay and the cut-off value. The first sub-group was represented by typical inflammatory demyelinat-
ing neuropathies, namely GBS (AIDP variant) and CIDP (n = 14). The diagnosis of definite GBS was based on 
published criteria, whereas CIDP diagnosis was performed according to the criteria of the European Federation 
of Neurological Societies/Peripheral Nerve Society26, 27. We used, as control subjects, 15 patients affected by other 
non-demyelinating disorders including hydrocephalus (n = 1), myalgia (n = 2), dizziness (n = 1), motor neuron 
disease (n = 2), epilepsy (n = 2), cognitive impairment (n = 3), meningioma (n = 1), chronic vascular enceph-
alopathy (n = 1) and axonal neuropathy (n = 2). Finally, 13 patients with obvious BBB dysfunction, as shown 
by CSF analysis and affected by non-demyelinating diseases, according to instrumental and clinical data, were 
used as a second group of control. These patients included, motor neuron disease (n = 1), cognitive impairment 
(n = 3), chronic vascular encephalopathy (n = 3) and axonal neuropathy (n = 6).
MCV and cMAP, recorded on peroneal nerves at the time of spinal tap, were considered and related to SM 
levels only for the sub-group of demyelinating neuropathies as neurophysiological studies are part of diagnostic 
criteria for these patients.
Human sample treatment and storage. CSF (3 ml) and peripheral blood (5 ml) were collected from 
all the subjects involved in the study and immediately sent to the laboratory for routinely diagnostic purposes. 
Immunochemical examination of CSF and serum was performed according to the recommendations of the 
Italian Association for Neuroimmunology28. In particular, the CSF to serum albumin concentration quotient 
(QAlb) is routinely used to evaluate blood-CSF barrier integrity. QAlb values higher than the cut-off suggested 
by international guidelines are considered positive for BBB dysfunction. The CSF to serum immunoglobulin G 
concentration quotient (QIgG) reflects both the rate of IgG permeability into the CSF from the blood and the 
intrathecal synthesis of IgG29. Samples were stored at RT during these steps. Exceeding amounts of CSF (at least 
1 ml of CSF and 1 ml of peripheral blood serum) were sent to the Neuropathology Laboratory of DINOGMI 
the same day of spinal tap, and immediately frozen and stored at −80 °C in 500 μl aliquots to perform SM dos-
age, avoiding repeated freezing and thawing. This latter procedure is fundamental to preserve lipid and protein 
integrity over time and consistent with the guidelines for uniform reporting of body fluid biomarker studies in 
neurologic disorders30.
Lipid extraction. Lipids were extracted from rat sciatic nerve, liver, spleen, and lung and purified myelin, 
following the detergent/heating method25. DRG homogenates and human CSF lipids were extracted following the 
Bligh and Dyer method31.
SM fluorescence-based assay. We recently optimised a fluorescence-based assay to quantify SM in 
tissue homogenates and biological fluids. All chemicals used in the following procedures were purchased by 
Sigma-Aldrich. This assay is based on lipid extraction from tissues, cells and fluids followed by enzymatic reac-
tions consisting in the following steps: 1) hydrolysis of SM to phosphorylcholine and ceramide by sphingomyeli-
nase; 2) hydrolysis of phosphorylcholine by alkaline phosphatase yielding choline and 3) oxidation of choline by 
choline oxidase with formation of hydrogen peroxide and betaine. Hydrogen peroxide, in the presence of horse-
radish peroxidase is able to react 1:1 with dihydroxyphenoxazine (AR) to generate resorufin, a highly fluorescent 
product25, 32. In particular, 5–10 μl of lipid extract from rat tissue homogenates and DRG cultures, human CSF and 
serum was added to individual wells of a 96-well microtiter plate that contained an enzymatic cocktail consisting 
of 12.5 mU of Bacillus cereus sphingomyelinase, 400 mU of alkaline phosphatase, 120 mU of choline oxidase, 200 
mU of horseradish peroxidase, and 20 nmol of AR in 100 μl of reaction buffer (50 mM Tris-HCl, 5 mM MgCl2, 
pH 7.4). For each sample, the relative negative control obtained removing sphingomyelinase by the reaction 
mixture was also analyzed. After 20 min incubation at 37 °C in the dark, the microtiter plate was read using a 
fluorescence microplate reader with excitation and emission wavelength at 560 and 587 nm, respectively (Infinite 
200 PRO, Tecan Italia Srl). A standard curve was prepared by making serial dilutions (from 0.0125 to 1.6 nmol) 
from a 2.8 nmol/μl of SM standard stock solution. For each sample SM levels were calculated from the difference 
in fluorescence between the sample and its relative negative control. Resulting values were interpolated with the 
related standard curve to obtain absolute SM concentration (nmol). SM levels for tissues homogenates, purified 
myelin, and DRG cultures were normalized to the weight, total protein content, and total volume, respectively.
Quantification of sphingomyelins by LC-MS/MS. Targeted analysis of sphingomyelins was performed 
using the method already published33.
Statistical analysis. Results are presented as mean ± SEM unless otherwise specified. Goodness of fit (r2) 
was determined by linear regression analysis. Statistical differences between two groups were determined using 
the two-tailed Student’s t-test. Multiple group comparison was performed by one-way ANOVA followed by the 
Holm-Sidak test. Correlation coefficient was estimated by the Spearman’s rank correlation test. We evaluated 
our test performances in terms of accuracy by using the ROC curve. In particular, we used our customized ROC 
implementation in Mathworks MATLAB environment34. Statistical differences were considered to be significant 
when p < 0.05. All statistical analysis was performed using the Graph Pad 7.0 (Prism) software.
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